Synonym: Danoprevir, RG7227
ITMN-191 (Danoprevir, RG7227) is a potent and orally active inhibitor of hepatitis C virus (HCV) NS3/4A serine protease with an IC50 of 1.6 nM. ITMN-191 is shown to be a potent inhibitor of NS3 with a two-step binding mechanism. Progress curves are consistent with the formation of an initial collision complex (EI) that isomerizes to a highly stable complex (EI*) from which ITMN-191 dissociates very slowly. From progress curve analysis, the rate constant for dissociation of ITMN-191 from the EI* complex is 3.8 x 10(-5) s(-1) with a calculated complex half-life of approximately 5 h and a true biochemical potency (K(i)*) of approximately 62 pM. Abrogation of the tight binding and slow dissociative properties of ITMN-191 is observed with proteases that carry the R155K or D168A substitution, each of which is likely in compound resistant mutants. Slow dissociation is not observed with closely related macrocyclic inhibitors of NS3, suggesting that members of this class may display distinct binding kinetics.
|Cell lines||Huh7 cells|
|Preparation method||The viability of Huh7 cells, human cardiac myocytes, and human cardiac fibroblasts was assessed following 72 h of exposure to ITMN-191 using a CellTiter-Glo Luminescent Cell Viability kit (Promega, Madison, WI). For these cell types, viability in the presence of ITMN-191 was fitted to a four-parameter logistic function to obtain a 50% cytotoxic concentration (CC50). Additionally, the CC50s were determined for six primary normal human cell types in stationary and proliferating (dividing) phases by Lonza, Inc. (Walkersville, MD). The cell types included normal human hepatocytes, microvascular endothelial cells, human skeletal muscle myoblasts, human articular chondrocytes, human lung fibroblasts, and renal proximal tubule epithelial cells. For the proliferating phase, ITMN-191 was added when cells reached 50% confluence. For the stationary phase, ITMN-191 was added 1 day after cells reached 100% confluence. Cell viability was quantified following 72 h of exposure to ITMN-191 using a ViaLight Plus kit on a microplate reader. CC50s were determined as described above.|
|Concentrations||5 pM ~100 nM|
|Incubation time||72 h|
|Animal models||Sprague-Dawley rats and Cynomolgus monkeys|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO ≥100 mg/mL
Ethanol ≥100 mg/mL
Characterization of HCV quasispecies dynamics upon short term dual-therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Le Pogam et al. Antimicrob Agents Chemother. 2012 Aug 6. PMID: 22869576.
Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: A computational study.
Pan et al. Biochim Biophys Acta. 2012 Oct;1820(10):1526-34. PMID: 22698669.
Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Reddy et al. Clin Pharmacokinet. 2012 Jul 1;51(7):457-65. PMID: 22624502.
Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey et al. Antivir Ther. 2012;17(5):927-32. PMID: 22611092.
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD, et al. Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41. PMID: 18824605.
|Related Proteasome Products|
|Sivelestat sodium tetrahydrate
Sivelestat sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, also inhibits leukocyte elastase obtained from rabbit, rat, hamster and mouse.
MG-101 is a potent inhibitor of cysteine proteases including calpain I (Ki = 190 nM), calpain II (Ki = 220 nM), cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM). IC50 value: 150 nM (Ki)
VR23 is a small molecule that potently inhibited the activities of trypsin-like proteasomes (IC50 = 1 nM), chymotrypsin-like proteasomes (IC50 = 50-100 nM), and caspase-like proteasomes (IC50 = 3 μM).
Gabexate Mesylate is a serine protease inhibitor with IC50 of 0.19 μM which is used therapeutically in the treatment of pancreatitis and disseminated intravascular coagulation.
CEP-18770 is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.